MicroRNAs in the Blood-Brain Barrier in Hypoxic-Ischemic Brain Injury

Guofang Shen¹ and Qingyi Ma¹,*

¹Department of Basic Sciences, The Lawrence D. Longo Center for Perinatal Biology, Loma Linda University School of Medicine, Loma Linda, CA 92350, USA

Abstract: Hypoxic-ischemic (HI) brain injury is a leading cause of acute mortality and chronic disability in newborns. Current evidence shows that cerebral microvascular response and compromised blood-brain barrier (BBB) integrity occur rapidly and could primarily be responsible for the brain injury observed in many infants with HI brain injury. MicroRNAs (miRNAs) are a type of highly conserved non-coding RNAs (ncRNAs), which consist of 21-25 nucleotides in length and usually lead to suppression of target gene expression. Growing evidence has revealed that brain-enriched miRNAs act as versatile regulators of BBB dysfunctions in various neurological disorders including neonatal HI brain injury. In the present review, we summarize the current findings regarding the role of miRNAs in BBB impairment after hypoxia/ischemia brain injury. Specifically, we focus on the recent progress of miRNAs in the pathologies of neonatal HI brain injury. These findings can not only deepen our understanding of the role of miRNAs in BBB impairment in HI brain injury, but also provide insight into the development of new therapeutic strategies for preservation of BBB integrity under pathological conditions.

Keywords: Hypoxic ischemia encephalopathy (HIE), ischemic stroke, miRNA, BBB disruption, MMP, tight junction, neural inflammation.

1. INTRODUCTION

Hypoxic-ischemic encephalopathy (HIE) is the brain injury caused by deprivation of oxygen or impaired cerebral blood flow to the brain in conditions such as placental insufficiency, umbilical cord occlusion, asphyxia, cardiac arrest, and others. The term HIE is sometimes used interchangeably with neonatal encephalopathy (NE) in the literature [1]. It is estimated that HIE occurs in about 1.5 per 1000 live births [2, 3] and is usually associated with severe long-term disabilities including cognitive impairments, epilepsy and cerebral palsy [3, 4]. Similar to ischemic stroke, brain injury in HIE also results from a cascade of pathological events triggered by hypoxia/ischemia and evolves over time [3-6]. The cerebral vascular cells are negatively affected over the course of HI pathology, leading to the opening of the blood-brain barrier (BBB), the structure that restricts material exchange between the blood and the brain parenchyma. Neonatal HIE showed rapid BBB disruption hours after the onset of HI insult in animal models [7-10]. Consistently, a clinical study found increased serum albumin in cerebrospinal fluid of neonates suffering from HI brain injury, and the permeability of BBB increased with the progression of HIE [11]. Therapeutic hypothermia is by far the only treatment available for HIE. Clinical trials have shown a reduction of infant death and disability due to hypothermia therapy, but death and disability in infants with severe to moderate HIE remain to be a big challenge for HIE treatment [12].

MicroRNAs (miRNAs) are a class of small non-coding RNAs that are well known for their ability to post-transcriptionally modulate gene expression. They are increasingly recognized as master regulators of cellular processes through regulating one-third of the genes encoded. Mature miRNAs are single-stranded RNAs of 21-25 nucleotides in length and target specific messenger RNAs (mRNAs) for degradation or suppression by complementary binding to their 3’ untranslated region (3’ UTR) [13, 14]. Encoded by about 1% of the genomic transcripts, thousands of miRNAs have been found in the human genome [15]. Cumulating evidence suggests that miRNAs may play a very important role in brain development and pathogenesis of neurological diseases such as ischemic stroke [13, 16, 17]. In the adult brain, the role of miRNAs in the modulation of BBB functions has been widely studied, and therapies based on miRNAs have shown to improve some outcomes of stroke in preclinical models of ischemic stroke. However, a majority of these studies focus on the mature brain, while BBB disruption and protection in the developing brain is less studied. Our understanding of the regulation of the BBB in the developing stage is still limited, thus the summary of findings from the adult brain could help us gain insights into BBB manipulations in the developing brain. However, cautions should be taken while extrapolating the data in consideration of the differences in the BBB between the mature and immat-
ture brain. Herein, we have reviewed current knowledge on the BBB in the developing brain. We have summarized the progress of miRNAs in the modulation of BBB functions in ischemic stroke and highlighted several miRNAs that are implicated in the pathogenesis of neonatal HI brain injury.

2. COMPONENTS AND STRUCTURE OF THE BLOOD-BRAIN BARRIER IN THE IMMATURE BRAIN

The BBB is a diffusion barrier primarily located at the cerebral capillaries. In the traditional concept, the BBB includes brain microvascular endothelial cells (ECs), pericytes, astrocytes and basement membrane, while a more conventional concept of the neurovascular unit (NVU) also includes perivascular microglia, smooth muscle cells and neurons. This so-called NVU plays important roles in neurovascular coupling and maintaining vascular homeostasis in CNS [18-22]. The barrier function of BBB is primarily attributed to a non-fenestrated layer of ECs that are assembled by junctional complexes consisting of tight junctions (TJs) and adherens junctions (AJs). The TJs seal the intercellular cleft and restrict paracellular transport, while the AJs are responsible for initiating and stabilizing endothelial cell-cell contact [23, 24]. There are now over 40 proteins identified within TJs, including Claudins, occluding, and zona occludens (ZO) [25]. The barrier function of the ECs is complemented and regulated by the cellular and non-cellular components of the NVU.

Despite the early belief that the BBB is ‘leaky’ in the immature brain, experimental evidence reported that the BBB is fully functional during brain development [26, 27]. It was shown that TJ proteins such as occludin and claudin 5 are present in the barrier interface soon after the first vessels invade the brain [27]. The endothelial permeability is tightly restricted at embryonic day (E) 15 and the tight junctions are completely differentiated at E19 in mice [28]. ECs, pericytes, and basement membrane are all present in the BBB, while astrocytes are mostly absent at the early stage of BBB development [27]. Astrogenesis starts around E18 and lasts around a week [29]. The mature astrocytes are critically involved in regulating BBB function [27, 28, 30].

3. MECHANISMS FOR BBB DISRUPTION AFTER BRAIN ISCHEMIA

The cellular responses of the BBB and mechanisms of BBB dysfunction after ischemic stroke have been comprehensively reviewed elsewhere [31, 32]. Briefly, the injured ECs show cytoskeletal rearrangement and increased transcytosis of the TJ associated proteins, leading to the opening of BBB. Increased adhesion of immune cells to the injured endothelium further promotes TJ protein redistribution and immune cell infiltration [33]. Infiltrated neutrophils as well as other injured cells produce matrix metalloproteinases (MMPs), a type of calcium-dependent zinc-containing endopeptidase that contributes to the degradation of TJs and extracellular matrix (ECM) [31]. Cytokines and chemokines released during neuroinflammation further exacerbate BBB breakdown by activating healthy ECs and modifying TJ proteins. It is recently confirmed that BBB disruption proceeds infarction development and blocking of early BBB dysfunction provides parenchymal protection in the ischemic stroke model in mice [34, 35].

In the developing brain, the vulnerability of BBB to hypoxia/ischemia varies depending on the developmental stage. In the preterm brain, BBB in the germinial matrix has relatively low pericyte coverage, few astrocytic ensheathment, immature basal membrane, and high local production of endothelial growth factor (VEGF), angiopoietin-2 (angpt2) and MMPs that make the preterm brain prone to hemorrhage [36]. This condition is changed at term. Studies from neonatal arterial stroke animal models using transient middle cerebral artery occlusion (tMCAO) revealed that the BBB in the brain at term is more resistant to ischemic insult [37]. They found that some BBB-associated proteins that were profoundly changed in the adult stroke, such as collagen type IV α1 (col4a1), col4a2 and ECM proteins were better preserved in experimental HIE. Yet BBB disruption and brain edema were still rapidly observed in experimental HIE, especially in cases where a more severe injury is implemented [7, 8, 10]. In clinic, 86% of term neonates suffering from severe HIE develop brain edema, which is usually associated with poor neurological outcome [38]. Consistently, experimental HIE showed decreased TJ proteins such as claudin-5, occludin and ZO-1 [7, 8], as well as increased infiltration of neutrophil and other immune cells [10]. Increased MMP-9 and inflammatory cytokines are found in the serum of neonates with HIE [39]. Those changes are similar, though they may be less severe compared to the adult brain under the same conditions [36]. However, evidence on the cellular and molecular mechanisms for BBB disruption and repair in HIE is still limited. The data from ischemic stroke may not fully apply to HIE. Future efforts are needed to study the mechanism of BBB disruption, as well as its impact on the progress of neuropathology in the immature brain.

4. BIOGENESIS OF miRNAs

MiRNA genes are mainly located in either non-coding areas or introns within coding genes in the genome. The biogenesis of miRNAs has been described in detail elsewhere [40]. In the canonical pathway, the primary miRNAs (pri-miRNAs) are transcribed by polymerase II from miRNAs genes. Those long pri-miRNAs are then processed by RNAse III protein Drosha to form precursor miRNA (pre-miRNAs) which is then transported to the cytoplasm. In the cytoplasm, the pre-miRNAs are cleaved by another RNAse III protein Dicer and TRBP, giving rise to miRNA duplex. One strand of the duplex is selected to incorporate into the RNA-induced silencing complex (RISC) which degrades miRNAs in the guidance of loaded miRNA sequence. A few miRNAs are processed through non-canonical pathways that are independent of Drosha or Dicer [40, 41]. It is proposed that miRNAs act in networks. One miRNA influences multiple transcripts within the targeted signaling network, and several miRNAs can target a single mRNA or multiple miRNAs in a signaling pathway to achieve a biological effect [42]. The level of mature miRNA in cells is subjected to transcriptional regulations and RNA modifications that interfere with the maturation process [40, 43]. Thus, miRNAs are sensitive to environmental factors and external stimuli, such as the presence of growth factors, inflammation or hypoxia.
MiRNAs are also found extracellularly [44, 45]. They exist in biological fluids including blood plasma, cerebrospinal fluid, saliva, urine, breast milk, tears and many others [46], in which miRNAs are packaged in membrane vesicles such as apoptotic bodies, shedding vesicles and exosomes [47, 48], or bound to Argonaute (AGO) proteins which stabilize them from being degraded by RNases in the body fluids [49]. A diverse range of cell types contributes to the pool of extracellular miRNAs which may be part of the communication system between different cells or organs [50]. A number of studies have reported that miRNAs are packed in apoptotic bodies, and exosomes can be taken up by recipient cells and exert functional effects [50]. Therefore, both locally synthesized miRNAs and those found in the circulation system may be involved in the regulation of the BBB.

5. POTENTIAL ROLE OF miRNAs IN BBB DISRUPTION

The role of miRNAs in stroke and BBB protection has been widely studied. Many differentially expressed miRNAs can positively or negatively manipulate BBB functions in in vitro and/or in vivo model for stroke [32]. These miRNAs may fall into different categories according to their targets.

5.1. MiRNAs and Junction Proteins

Tight junction protein degradation is a major contributor to BBB disruption. The TJ and AJ proteins such as claudins, occludins and cadherins are subjected to degradation by MMPs, which is directly regulated by miRNAs. For instance, the expression of miR-132 was increased in the blood of stroke patients. Agomir-132 (exogenous miR-132) suppressed the transcript of MMP-9 and decreased the degradation of VE-cadherin in a mouse model of ischemic stroke [51]. Another study showed increased miR-539 expression in the brain tissue in rats after ischemia, which directly inhibits MMP-9 expression and protects ECs from oxygen-glucose deprivation (OGD)-induced EC monolayer hyperpermeability [52]. Moreover, other miRNAs have been found to directly target signaling pathways that regulate the expression, distribution and degradation of the junctional proteins. For example, miR-150 increased BBB permeability by targeting Tie-2 [53], an angiopoietin receptor that positively regulates vascular barrier function [54, 55]. MiR-143, which was upregulated after ischemic stroke in both human and animal models, was shown to target the E3 ubiquitin-protein ligase Hectd1 and enhance endothelial-mesenchymal transition associated with BBB disruption [56]. MiR-130a, which predominantly increased in ECs after ischemia, decreased tight junction protein expression by binding to transcription factor homeobox A5 [57]. MiR-155 targets claudin 1, and inhibition of which increases claudin1 and ZO-1 expression in human brain microvascular ECs [58]. In addition, miRNAs have been found to regulate junctional protein in other brain disorders [32].

5.2. MiRNAs and Cellular Components of the BBB

Endothelial cell injury after HI insult is the initial phase of BBB disruption. Thus, modulation of miRNAs related to endothelial cell damage is beneficial for preserving the BBB integrity. For example, miR-34a is upregulated in ECs after HI insult, which negatively affects mitochondria function in ECs by targeting Cytochrome c. Moreover, miR-34a knock-out reduces BBB permeability, alleviates disruption of tight junctions, and improves stroke outcomes [59, 60]. MiR-26b inhibits autophagy and survival of ECs under OGD by targeting ULK2 and its endogenous sponge malat1 overturns the effect of miR-26b [61]. MiR-15a is upregulated in mouse cerebral ECs after OGD and induces EC death by targeting bel-2. Further study showed that miR-15a is negatively regulated by peroxisome proliferator-activated receptor (PPAR) delta, a potential neuroprotectant in ischemic stroke [62]. Besides the primary contribution of ECs to the barrier function of the BBB, other cellular components such as astrocytes and pericytes also contribute to the regulation of the BBB permeability. Pericytes are the important regulator of BBB functions. Upon HI insult, pericytes separate and migrate away from the basement membrane, contributing to the BBB dysfunction. MiR-149-5p exerts its BBB protective effect by regulating pericyte migration. Further mechanical study revealed that miR-149-5p increased N-cadherin expression and decreased cell migration by negatively regulating sphingosine-1-phosphate receptor (SIPR) 2 and its downstream NF-κβ/p65 pathway in cultured pericyte exposed to OGD [63]. Aquaporin-4 (AQP-4) is an active regulator of water flux, which is primarily expressed on the end-feet of astrocytes and plays an important role in edema formation. It has been documented that overexpression of miR-29b down-regulates AQP-4 and reduces cerebral edema in mice model of ischemic stroke [64]. Moreover, miR-130a and miR-320 were also shown to be transcription repressor and inhibitor of AQP-4 [65, 66]. However, cautions should be taken when designing therapeutics based on AQP-4 due to its reported ability to increase vasogenic edema [67]. AQP-4 activity is mainly associated with reduced cerebral edema in the neonatal brain [68].

5.3. MiRNAs and Neuroinflammation

Neuroinflammation is greatly increased after neonatal HI insult. The BBB at the interface of the blood and the brain parenchyma is prone to injury induced by immune cell infiltration and cytokine signaling. Some miRNAs can protect BBB integrity by reducing immune cell adhesion and pro-inflammatory cytokine expression. For instance, overexpression of miR-126-3p and -5p in the ischemic mice brain down-regulated pro-inflammatory cytokines and adhesion molecules, preserving BBB integrity and improving stroke outcome [69]. MiR-146a expression was increased in the brain tissue in a mouse model of ischemia stroke. Inhibition of miR-146a was shown to exacerbate BBB leakage after ischemic stroke by over-activating NF-κb signaling, increasing expression of inflammatory cytokines and its direct target, interleukin-1 receptor-associated kinase 1 (IRAK1) [70]. MiR-98, which is significantly reduced in the ECs after HI insults, was shown to reduce BBB permeability, leukocytes infiltration and microglia activation [71]. In addition to anti-inflammation, a number of miRNAs were shown to exhibit pro-inflammatory effect and exacerbate BBB function after ischemic stroke. For instance, miR-210 up-regulates the expression of TNF-α, IL-18, IL-6 CCL1 and CCL2 that are associated with pro-inflammatory response in a mouse model of ischemic stroke [72]. MiR-155 is strongly induced
by cytokines and mediates cytokine-induced hyperpermeability in ECs monolayer, whereas inhibition of miR-155 partially prevented monolayer damage [73]. Therapies based on those miRNAs may also show a potential protective effect on the BBB.

6. MIRNA IN THE DEVELOPING BRAIN AFTER HI BRAIN INJURY

Comparing to the large amount of studies investigating the role of miRNAs in brain injury in adults, only a few studies have focused on the expression of miRNAs in neonatal HIE [16]. Several miRNAs were found to be associated with HIE. For instance, miR-210 is up-regulated in the maternal blood of severely growth-restricted infants [74] and in the mouse hemisphere after HI brain injury [75]. MiR-210 is a master hypoxamir, which is regulated by HIF-1α and NF-κB during hypoxia [76]. It has been reported that miR-210 exerts a wide range of biological activities, including mitochondrial metabolism, angiogenesis and cell differentiation [13, 76]. In the normal brain, overexpression of miR-210 promotes angiogenesis and neurogenesis [77]. Our study found that HI insult significantly overexpressed miR-210 levels in the neonatal brain, which exacerbated BBB permeability by downregulating the expression of occludin and β-catenin after HI insult [78]. Moreover, inhibition of miR-210 exerted neuroprotective effect as well as anti-inflammation effect in the neonatal and adult brain [75, 79, 80]. Other studies have shown that miR-210 mediates the protective effect of vagus nerve stimulation on ischemic stroke and promotes neural precursor cell accumulation around ischemic region [81, 82]. It is possible that miR-210 have multiple targets in the brain to exert multiple functions that differ at injury and recovery stage of ischemic stroke and neonatal HIE. As a potential therapeutic target for HIE, more studies are needed to further determine the effect of miR-210 over the course of HI brain injury in neonates.

In addition to miR-210, other miRNAs, including miR-21, miR-374a, miR-424, miR-199a and miR-20b, are also potentially associated with neonatal HIE [74, 83]. MiR-21 upregulated TJP proteins in an animal model of traumatic brain injury [84] and a neuroprotective effect of miR-21 in ischemic stroke was also reported [85]. The effects of miR-374a, miR-199a and miR-424 have also been studied in ischemic stroke. However, their effects in the neonatal HIE are yet to be determined. Moreover, miR-146a, miR-155, miR-124 and let-7i have been implicated for the regulation of neuroinflammation, mainly microglia related response in the neonatal brain [86]. Among them, the miR-146a and let-7i showed a protective effect toward hypoxia in the neonatal brain [87, 88]. How neuroinflammation contributes to the BBB disruption in the neonatal brain after HI insult remains to be studied.

CONCLUSION

BBB protection has been widely recognized as a potential therapeutic strategy for the treatment of ischemic stroke. Cumulating evidence has shown that miRNA-based therapies such as miRNA mimics and inhibitors can manipulate miRNAs in the brain and protect BBB integrity in experimental models. However, those therapies are facing major experimental challenges such as the lack of efficient drug delivery system to the brain, short half-life of the therapeutic molecules and the presence of off-target effects [89]. There may be still a long way to go to achieve success in the clinical translation of those therapeutics. Moreover, the molecular and cellular mechanism of BBB dysfunction in neonatal HI brain injury remains to be elucidated. The role of miRNAs in the pathogenesis of HIE is largely unknown. Despite the rich knowledge on BBB protection in ischemic stroke, the physiological difference between the developing and mature brain may limit the applicability of the data extrapolated from ischemic stroke. Future studies are needed to fill in the gap regarding BBB protection in the developing brain.

CONSENT FOR PUBLICATION

Not applicable.

FUNDING

This work was supported by NIH grant 1R01NS112404-01 from NINDS to Q.M.

CONFLICT OF INTEREST

The authors declare no conflict of interest, financial or otherwise.

ACKNOWLEDGEMENTS

We apologize to the authors whose excellent studies covered in the scope of this review were unable to be cited due to space restrictions.

REFERENCES

[1] Molloy, E.J.; Bearer, C. Neonatal encephalopathy versus Hypoxic-Ischemic Encephalopathy. Pediatr. Res., 2018, 84(5), 574. http://dx.doi.org/10.1038/s41390-018-0169-7 PMID: 30214023
[2] Kurinczuk, J.J.; White-Koning, M.; Badawi, N. Epidemiology of neonatal encephalopathy and hypoxic-ischaemic encephalopathy. Early Hum. Dev., 2010, 86(6), 329-338. http://dx.doi.org/10.1016/j.earlhumdev.2010.05.010 PMID: 20554402
[3] Allen, K.A.; Brandon, D.H. Hypoxic Ischemic Encephalopathy: Pathophysiology and Experimental Treatments. Newborn Infant Nurs. Rev., 2011, 11(3), 125-133.
[4] Douglas-Escobar, M.; Weiss, M.D. Hypoxic-ischemic encephalopathy: a review for the clinician. JAMA Pediatr., 2015, 169(4), 397-403. http://dx.doi.org/10.1001/jamapediatrics.2014.3269 PMID: 25685948
[5] Stamatovic, S.M.; Phillips, C.M.; Martinez-Revoltar, G.; Keep, R.F.; Andjelkovic, A.V. Involvement of Epigenetic Mechanisms and Non-coding RNAs in Blood-Brain Barrier and Neurovascular Unit Injury and Recovery After Stroke. Front. Neurosci., 2019, 13, 864. http://dx.doi.org/10.3389/fnins.2019.00864 PMID: 31543756
[6] Vasiljevic, B.; Maglajlic-Djukic, S.; Gojnic, M.; Stankovic, S.; Ignjatovic, S.; Lutovac, D. New insights into the pathogenesis of perinatal hypoxic-ischemic brain injury. Pediatr. Int., 2011, 53(4), 454-462. http://dx.doi.org/10.1111/j.1442-200X.2010.03290.x PMID: 21077993
[7] Ek, C.J.; D’Angelo, B.; Baburamani, A.A.; Lehner, C.; Leverin, A.L.; Smith, P.L.; Nilsson, H.; Svedin, P.; Hagberg, H.; Mallard, C. Brain barrier properties and cerebral blood flow in neonatal mice exposed to cerebral hypoxia-ischemia. J. Cereb. Blood Flow Metab., 2015, 35(5), 818-827. http://dx.doi.org/10.1038/jcbbf.2014.255 PMID: 25627141
[8] Chen, X.; Threlkeld, S.W.; Cummings, E.E.; Juan, I.; Makeev, O.; Besio, W.G.; Gaitanis, J.; Banks, W.A.; Sadowska, G.B.; Stonestreet, B.S. Ischemia-reperfusion impairs blood-brain barrier function and alters tight junction protein expression in the ovine fetus. *Neuroscience, 2012*, 226, 89-100. http://dx.doi.org/10.1016/j.neuroscience.2012.08.043 PMID: 22986172

[9] Ferrari, D.C.; Nesic, O.B.; Perez-Polo, J.R. Oxygen reperfusion does not ameliorate neonatal hypoxia-ischemia-induced cerebral edema. *J. Neurosci. Res., 2010*, 88(9), 2056-2065. http://dx.doi.org/10.1002/jnr.22358 PMID: 20431441

[10] Benjelloun, N.; Renolleau, S.; Repasa, A.; Ben-Ari, Y.; Charriaut-Marlangue, C. Inflammatory responses in the cerebral cortex after ischemia in the P7 neonatal rat. *Stroke, 1999*, 30(9), 1916-1923. http://dx.doi.org/10.1161/10513514 PMID: 10471445

[11] Kumar, A.; Mittal, R.; Khanna, H.D.; Basu, S. Free radical injury and blood-brain barrier permeability in hypoxic-ischemic encephalopathy. *Pediatrics, 2008*, 122(3), e722-e727. http://dx.doi.org/10.1542/peds.2008-0269 PMID: 18725389

[12] Moretti, R.; Pansiot, J.; Bettati, D.; Strazielle, N.; Ghersi-Egas, J.F.; Damante, G.; Fleiss, B.; Tito, M.; Gressens, P. Blood-brain barrier dysfunction in disorders of the developing brain. *Front. Neurosci., 2015*, 9, 40. http://dx.doi.org/10.3389/fnins.2015.00040 PMID: 25741233

[13] Ma, Q.; Zhang, L.; Pearce, W.J. MicroRNA in brain development and cerebrovascular pathophysiology. *Am. J. Physiol. Cell Physiol., 2019*, 317(1), C3-C19. http://dx.doi.org/10.1152/ajpcell.00022.2019 PMID: 30840494

[14] Inui, M.; Martello, G.; Piccolo, S. MicroRNA control of signal transduction. *Nat. Rev. Mol. Cell Biol., 2010*, 11(4), 252-263. http://dx.doi.org/10.1038/nrm2868 PMID: 20216554

[15] Sun, W.; Julie Li, Y.S.; Huang, H.D.; Shyy, J.Y.; Chien, S. microRNA: A master regulator of cellular processes for bioengineering systems. *Annu. Rev. Biomed. Eng., 2010*, 12, 1-27. http://dx.doi.org/10.1146/annurev-bioeng-070909-105314 PMID: 20415587

[16] Ponnapasamy, V.; Yip, P.K. The role of microRNAs in newborn brain development and hypoxic ischaemic encephalopathy. *Neuropharmacology, 2019*, 149, 55-65. http://dx.doi.org/10.1016/j.neuropharm.2018.11.041 PMID: 30716413

[17] Rink, C.; Khanna, S. MicroRNA in ischemic stroke etiology and pathology. *Physiol. Genomics, 2011*, 43(10), 521-528. http://dx.doi.org/10.1152/physiogenomics.00015.2010 PMID: 20641499

[18] Rosenberg, G.A. Ischemic brain edema. *Prog. Cardiovasc. Dis., 1999*, 42(3), 209-216. http://dx.doi.org/10.1016/S0033-0620(99)70003-4 PMID: 10598921

[19] Yao, Y. Basement membrane and stroke. *J. Cereb. Blood Flow Metab., 2019*, 39(1), 3-19. http://dx.doi.org/10.1177/0271678818801467 PMID: 30226080

[20] Ballabh, P.; Braun, A.; Neder NRA, M. The blood-brain barrier: an overview: structure, regulation, and clinical implications. *Neurobiol. Dis., 2004*, 16(1), 1-13. http://dx.doi.org/10.1016/j.nbd.2003.12.016 PMID: 15207256

[21] Hawkins, B.T.; Davis, T.P. The blood-brain barrier/neurovascular unit in health and disease. *Pharmacol. Rev., 2005*, 57(2), 173-185. http://dx.doi.org/10.1124/pr.57.2.4 PMID: 15914466

[22] Brown, L.S.; Foster, C.G.; Courtneym, J.M.; King, N.E.; Howells, A.J.; Makeev, O. Brain endothelial cell-cell junctions how to “open” the blood brain barrier. *Curr. Neuropharmacol., 2008*, 6(3), 179-192. http://dx.doi.org/10.2174/157015908785777210 PMID: 19506719

[23] Anderson, J.M.; Van Itallie, C.M. Physiology and function of the tight junction. *Cold Spring Harb. Perspect. Biol., 2009*, 1(2), a002584. http://dx.doi.org/10.1101/cshperspect.a002584 PMID: 20066090

[24] Ek, C.J.; Dziegielewksa, K.M.; Habgood, M.D.; Saunders, N.R. Barriers in the developing brain and Neurotoxicology. *Neurotox. 2012*, 33(3), 586-604. http://dx.doi.org/10.1016/j.expneurol.2011.12.009 PMID: 22198708

[25] Saunders, N.R.; Liddelow, S.A.; Dziegielewksa, K.M. Barrier mechanisms in the developing brain. *Front. Pharmacol., 2012*, 3, 46. http://dx.doi.org/10.3389/fphar.2012.00046 PMID: 22479246

[26] Mallard, C.; Ek, C.J.; Vekler, Z.S. The myth of the immature barrier systems in the developing brain: role in perinatal brain injury. *J. Physiol., 2018*, 596(23), 5655-5664. http://dx.doi.org/10.1113/jphysiol.2017.172973 PMID: 29258501

[27] Cerutti, C.; Ridley, A.J. Endothelial cell-cell adhesion and signaling. *Exp. Cell Res., 2017*, 358(1), 31-38. http://dx.doi.org/10.1016/j.yexcr.2016.10.003 PMID: 28602626

[28] Gao, Y.; Leak, R.K.; Keep, R.F.; Bennett, M.V.; Chen, J. Endothelium-targeted overexpression of heat shock protein 27 ameliorates blood-brain barrier disruption and long-term ischemic reperfusion brain injury. *Nat. Commun., 2016*, 7, 10523. http://dx.doi.org/10.1038/ncomms10523 PMID: 26813496

[29] Marlangue, C. Inflammatory responses in the cerebral cortex after neonatal Rat. *Neurochem. Res., 2010*, 35(11), 2789-2798. http://dx.doi.org/10.1007/s11064-010-0359-9 PMID: 20123819

[30] Ferrari, D.C.; Nesic, O.B.; Perez-Polo, J.R. Perspectives on neonatal hypoxia/ischemia-induced edema formation. *Neurochem. Res., 2010*, 35(12), 1957-1965. http://dx.doi.org/10.1007/s11064-010-0368-y PMID: 21136160

[31] Lw, H.; Wang, Q.; Wu, S.; Yang, L.; Ren, P.; Yang, Y.; Gao, J.; Li, L. Neonatal hypoxic ischemic encephalopathy-related biomarkers in serum and cerebrospinal fluid. *Clin. Chim. Acta, 2015*, 450, 282-297. http://dx.doi.org/10.1016/j.cca.2015.08.021 PMID: 26320853

[32] Kreth, S.; Hübner, M.; Hinske, L.C. MicroRNAs as Clinical Biomarkers and Therapeutic Tools in Perioperative Medicine. *Anesth. Analg., 2018*, 126(2), 670-681. http://dx.doi.org/10.1097/AAP.0000000000002584
microRNAs and BBB Dysfunction

Chen, C.H.; Sun, Y.M.; Chang, W.C.; Chiang-Hsieh, P.Y.; Lee, T.Y.; Tsai, W.C.; Honig, J.T.; Tsou, A.P.; Huang, H.D. Identifying transcriptional start sites of human microRNAs based on high-throughput sequencing data. *Nucleic Acids Res.*, 2011, 39(21), 9345-9356.

Lawrie, C.H.; Gal, S.; Dunlop, H.M.; Pushkaran, B.; Liggin, A.P.; Pulford, K.; Banham, A.H.; Pezzella, F.; Boultwood, J.; Wainscoat, J.S.; Hatton, C.S.; Harris, A.L. Detection of elevated levels of tumour-associated microRNAs in serum of patients with diffuse large B-cell lymphoma. *Br. J. Haematol.*, 2008, 141(5), 672-675. http://dx.doi.org/10.1111/j.1365-2141.2008.07077.x PMID: 18318758

Chim, S.S.; Shing, T.K.; Hung, E.C.; Leung, T.Y.; Lau, T.K.; Chiu, R.W.; Lo, Y.M. Detection and characterization of placental microRNAs in maternal plasma. *Clin. Chem.*, 2008, 54(3), 482-490. http://dx.doi.org/10.1373/clinchem.2007.097972 PMID: 18218722

Turchinovich, A.; Weiz, L.; Burwinke, B. Extracellular miRNAs: the mystery of their origin and function. *Trends Biochem. Sci.*, 2012, 37(11), 460-465. http://dx.doi.org/10.1016/j.tibs.2012.08.003 PMID: 22944280

Zernecke, A.; Bidzukhev, K.; Noels, H.; Shagdasuren, E.; Gran, L.; Donecke, B.; Hristov, M.; Köppl, T.; Jahnuthkh, M.N.; Lutgens, E.; Wang, S.; Olson, E.N.; Schober, A.; Weber, C. Delivery of microRNA-126 by apoptotic bodies induces CXCL12-dependent vascular protection. *Sci. Signal.*, 2009, 2(100), ra81. http://dx.doi.org/10.1126/scisignal.2000610 PMID: 19964577

Valadi, H.; Ekström, K.; Bossios, A.; Sjöstrand, M.; Lee, J.J.; Lötvall, J.O. Exosome-mediated transfer of miRNAs and microRNAs is a novel mechanism of genetic exchange between cells. *Nat. Cell Biol.*, 2007, 9(6), 654-659. http://dx.doi.org/10.1038/ncl1596 PMID: 17486113

Arroyo, J.D.; Chevillet, J.R.; Kroh, E.M.; Ruf, I.K.; Pritchard, C.C.; Gibson, D.F.; Mitchell, P.S.; Bennett, C.F.; Pogosova-Agadjanyan, E.L.; Strewalt, D.L.; Tait, J.F.; Tewari, M. Argonaute 2 complexes carry a population of circulating microRNAs in dependence of vesicles in human plasma. *Proc. Natl. Acad. Sci. USA.*, 2011, 108(12), 5003-5008. http://dx.doi.org/10.1073/pnas.1019055108 PMID: 21383194

Turchinovich, A.; Samatov, T.R.; Tonevitsky, A.G.; Burwinke, B. Circulating miRNAs: cell-cell communication function? *Front. Genet.*, 2013, 4, 119. http://dx.doi.org/10.3389/fgene.2013.00119 PMID: 23825476

Zuo, X.; Lu, J.; Mannaenko, A.; Qi, X.; Tang, J.; Mei, Q.; Xia, Y.; Hu, Q. MicroRNA-132 attenuates cerebral injury by protecting blood-brain barrier in MCAO mice. *Exp. Neurol.*, 2019, 316, 12-19. http://dx.doi.org/10.1016/j.expneurol.2019.03.017 PMID: 30930097

Fan, F.; Yang, J.; Xu, Y.; Guan, S. MiR-539 Targets MPP-9 to Regulate the Permeability of Blood-Brain Barrier in Ischemia/Reperfusion Injury of Brain. *Neurochem. Res.*, 2018, 43(12), 2260-2267. http://dx.doi.org/10.1007/s11064-018-2646-0 PMID: 30276507

Fang, Z.; He, Q.W.; Li, Q.; Chen, X.L.; Baral, S.; Jin, H.J.; Zhu, Y.Y.; Li, M.; Xia, Y.P.; Mao, L.; Hu, B. MicroRNA-150 regulates blood-brain barrier permeability via Tie-2 after permanent middle cerebral artery occlusion in rats. *FASEB J.*, 2016, 30(6), 2097-2107. http://dx.doi.org/10.1002/febs.14619 PMID: 201500126 PMID: 26887441

Gamble, J.R.; Drew, J.; Trezise, L.; Underwood, A.; Parsons, M.; Kasminskas, L.; Rudge, J.; Yancopoulos, G.; Vadas, M.A. Angiopoetin-1 is an antiangiogenic and antiinflammatory agent in vitro and targets cell junctions. *Circ. Res.*, 2000, 87(7), 603-607. http://dx.doi.org/10.1161/01.RES.87.7.603 PMID: 11009566

Milam, K.E.; Parikh, S.M. The angiopoietin-Tie2 signaling axis in the vascular leakage of systemic inflammation. *Tissue Barriers*, 2015, 3(1-2), e957508. http://dx.doi.org/10.4161/tissue.31883.2014.e957508 PMID: 25838975

Bai, Y.; Zhang, Y.; Han, B.; Yang, L.; Chen, X.; Huang, R.; Wu, F.; Chao, J.; Liu, P.; Hu, G.; Zhang, J.H.; Yao, H. Circular RNA DLGAP4 Ameliorates Ischemic Stroke Outcomes by Targeting miR-143 to Regulate Endothelial-Mesenchymal Transition Associ-
ischemia-reperfusion injury. *Can. J. Physiol. Pharmacol.*, 2018, 96(6), 611-617. http://dx.doi.org/10.1139/cjpp-2017-0586 PMID: 29505740

[71] Bernstein, D.L.; Zuluaga-Ramirez, V.; Gajighe, S.; Reichenbach, N.L.; Polyak, B.; Persidsky, Y.; Rom, S. miR-98 reduces endothelial dysfunction by protecting blood-brain barrier (BBB) and improves neurological outcomes in mouse ischemia/reperfusion stroke model. *J Cereb Blood Flow Metab.*, 2019, 271678X19882264.

[72] Huang, L.; Ma, Q.; Li, Y.; Li, B.; Zhang, L. Inhibition of microRNA-210 suppresses pro-inflammatory response and reduces acute brain injury of ischemic stroke in mice. *Exp. Neurol.*, 2018, 300, 41-50. http://dx.doi.org/10.1016/j.expneurol.2017.10.024 PMID: 29111308

[73] Lopez-Ramirez, M.A.; Wu, D.; Pryce, G.; Simpson, J.E.; Reijerkerk, A.; King-Robson, J.; Kay, O.; de Vries, H.E.; Hirst, M.C.; Sharrant, B.; Baker, D.; Male, D.K.; Michael, G.J.; Romero, I.A. MicroRNA-155 negatively affects blood-brain barrier function during neuroinflammation. *FASEB J.*, 2014, 28(6), 2551-2565. http://dx.doi.org/10.1096/fj.2013-248880 PMID: 24604078

[74] Whitehead, C.L.; Teh, W.T.; Walker, S.P.; Leung, C.; Larmour, L.; Tong, S. Circulating MicroRNAs in maternal blood as potential biomarkers for fetal hypoxia in-utero. *PLoS One*. 2013, 8(11), e78487. http://dx.doi.org/10.1371/journal.pone.0078487 PMID: 24282500

[75] Ma, Q.; Dasgupta, C.; Li, Y.; Bajwa, N.M.; Xiong, F.; Harding, B.; Hartman, R.; Zhang, L. Inhibition of microRNA-210 provides neuroprotection in hypoxic-ischemic brain injury in neonatal rats. *Neurobiol. Dis.*, 2016, 89, 202-212. http://dx.doi.org/10.1016/j.nbd.2016.02.011 PMID: 26875527

[76] Chan, Y.C.; Banerjee, J.; Choi, S.Y.; Sen, C.K. miR-210: the master hypoxa. *Microcirculation*. 2012, 19(3), 215-223. http://dx.doi.org/10.1111/j.1549-8719.2011.00154.x PMID: 22171547

[77] Zeng, L.; He, X.; Wang, Y.; Tang, Y.; Zheng, C.; Cai, H.; Liu, J.; Wang, Y.; Fu, Y.; Yang, G.Y. MicroRNA-210 overexpression induces angiogenesis and neurogenesis in the normal adult mouse brain. *Gene Ther.*, 2014, 21(1), 37-43. http://dx.doi.org/10.1038/gt.2013.55 PMID: 24152581

[78] Ma, Q.; Dasgupta, C.; Li, Y.; Huang, L.; Zhang, L. MicroRNA-210 Suppresses Junction Proteins and Disrupts Blood-Brain Barrier Integrity in Neonatal Rat Hypoxic-Ischemic Brain Injury. *Int. J. Mol. Sci.*, 2017, 18(7), E1356. http://dx.doi.org/10.3390/ijms18071356 PMID: 28672801

[79] Li, Y.; Huang, L.; Ma, Q.; Concepcion, K.R.; Song, M.A.; Zhang, P.; Fu, Y.; Xiao, D.; Zhang, L. Repression of the Glucocorticoid Receptor Aggravates Acute Ischemic Brain Injuries in Adult Mice. *Int. J. Mol. Sci.*, 2018, 19(4), E2428. http://dx.doi.org/10.3390/ijms19042428 PMID: 30126083

[80] Li, B.; Dasgupta, C.; Huang, L.; Meng, X.; Zhang, L. MiRNA-210 induces microglial activation and regulates microglia-mediated neuroinflammation in neonatal hypoxic-ischemic encephalopathy. *Cell. Mol. Immunol.*, 2020, 17(9), 976-991. http://dx.doi.org/10.1038/s41423-019-0257-6 PMID: 31300734

[81] Jiang, Y.; Li, L.; Tan, X.; Liu, B.; Zhang, Y.; Li, C. miR-210 mediates vagus nerve stimulation-induced antioxidant stress and anti-apoptosis reactions following cerebral ischemia/reperfusion injury in rats. *J. Neurochem.*, 2015, 134(1), 173-181. http://dx.doi.org/10.1111/jnc.13097 PMID: 25783636

[82] Meng, Z.Y.; Kang, H.L.; Duan, W.; Zheng, J.; Li, Q.N.; Zhou, Z.J. MicroRNA-210 Promotes Accumulation of Neural Precursor Cells Around Ischemic Foci After Cerebral Ischemia by Regulating the SOCS1-STAT3-VEGF-C Pathway. *J. Am. Heart Assoc.*, 2018, 7(5), e005052. http://dx.doi.org/10.1161/JAHA.116.005052 PMID: 29478968

[83] Garberig, H.T.; Huyn, M.U.; Baumbusch, L.O.; Asegg-Anesosen, M.; Solberg, R.; Saugstad, O.D. Temporal Profile of Circulating microRNAs after Global Hypoxia-Ischemia in Newborn Piglets. *Neonatal*. 2017, 111(2), 133-139. http://dx.doi.org/10.1159/000449032 PMID: 27750254

[84] Ge, X.; Han, Z.; Chen, F.; Wang, H.; Zhang, B.; Jiang, R.; Lei, P.; Zhang, J. MiR-21 alleviates secondary blood-brain barrier damage after traumatic brain injury in rats. *Brain Res.*, 2015, 1603, 150-157. http://dx.doi.org/10.1016/j.brainres.2015.01.009 PMID: 25598202

[85] Yao, X.; Wang, Y.; Zhang, D. microRNA-21 Confers Neuroprotection Against Cerebral Ischemia-Reperfusion Injury and Alleviates Blood-Brain Barrier Disruption in Rats via the MAPK Signaling Pathway. *J. Mol. Neurosci.*, 2018, 65(1), 43-53. http://dx.doi.org/10.1007/s12031-018-1067-7 PMID: 29696468

[86] Cho, K.H.T.; Xu, B.; Blenkiron, C.; Fraser, M. Emerging Roles of miRNAs in Brain Development and Perinatal Brain Injury. *Front. Physiol.*, 2019, 10, 227. http://dx.doi.org/10.3389/fphys.2019.00227 PMID: 30984006

[87] Zhou, T.; Huang, Y.X.; Song, J.W.; Ma, Q.M. Thymosin β4 inhibits microglia activation through microRNA 146a in neonatal rats following hypoxia injury. *Neuroreport*. 2015, 26(17), 1032-1038. http://dx.doi.org/10.1097/WRN.0000000000000463 PMID: 26457369

[88] Mueller, M.; Zhou, J.; Yang, L.; Gao, Y.; Wu, F.; Schoeberlein, A.; Surbek, D.; Barnea, E.R.; Paidas, M.; Huang, Y. Preimplantation factor promotes neuroprotection by targeting microRNA let-7. *Proc. Natl. Acad. Sci. USA*. 2014, 111(38), 13882-13887. http://dx.doi.org/10.1073/pnas.1411674111 PMID: 25205808

[89] Sun, P.; Liu, D.Z.; Jickling, G.C.; Sharp, F.R.; Yin, K. MicroRNA-based therapeutics in central nervous system injuries. *J. Cereb Blood Flow Metab.*, 2018, 38(7), 1125-1148. http://dx.doi.org/10.1007/s00401-017-1972-0 PMID: 29708005